<DOC>
	<DOCNO>NCT00590174</DOCNO>
	<brief_summary>The purpose ZEST-LATE ( Evaluation Long-term Safety After Zotarolimus-Eluting Stent , Sirolimus-Eluting Stent , PacliTaxel-Eluting Stent Implantation Coronary Lesions - Late Coronary Arterial Thrombotic Events ) trial ass relationship long-term clopidogrel use beyond 1 year long-term rate death MI DES implantation estimate duration dual antiplatelet therapy prevent late thrombotic event .</brief_summary>
	<brief_title>Clopidogrel Use Long-term Safety After Drug-Eluting Stents Implantation</brief_title>
	<detailed_description>Prospective , two arm , open-labeled , randomized multi-center trial approximately 2,000 patient enrol 19 center Korea . Among patient enrol ZEST ( Comparison Efficacy Zotarolimus-Eluting Stent versus Sirolimus-Eluting Stent versus PacliTaxel-Eluting Stent Coronary Lesions ) trial , event-free patient survive first 12 month without nonfatal MI repeat revascularization randomize discontinue clopidogrel therapy 12 month DES implantation . All patient follow another 12 month .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>1 . Among participant ZEST trial , eventfree patient survive first 12 month without nonfatal MI repeat revascularization 2 . The patient guardian agrees study protocol schedule clinical followup , provide informed , write consent , approve appropriate Institutional Review Board/Ethical Committee respective clinical site . 1 . Contraindication antiplatelet therapy 2 . Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment ) . 3 . Patients actively participate another drug device investigational study , complete primary endpoint followup period . 4 . Bleeding diathesis 5 . Recent stroke within 6months 6 . Concurrent organ damage ( creatinine level &gt; 2.0mg/dL AST ALT &gt; 3 time upper normal reference value ) 7 . Patients leave main stem stenosis ( &gt; 50 % visual estimate )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>stent</keyword>
	<keyword>antiplatelet therapy</keyword>
</DOC>